Heart palpitations (perimenopausal)

What it is

Perimenopausal heart palpitations are sensations of a racing, fluttering, pounding, or skipped heartbeat affecting 20–42% of perimenopausal women and up to 54% of postmenopausal women, making them one of the most common — and most underrecognized — symptoms of the menopause transition. Also called menopausal palpitations or climacteric cardiac awareness, the symptom describes a temporary, often unsettling perception of one's own heartbeat that is not always accompanied by a measurable arrhythmia. During a hot flash, heart rate can rise by 8–16 beats per minute, which is one reason palpitations and vasomotor symptoms so frequently co-occur. For Canadian patients, this symptom is worth discussing with a clinician early: cardiovascular disease is the leading cause of death in Canadian women, and distinguishing benign menopausal palpitations from an underlying arrhythmia requires clinical assessment.

Causes and mechanism

The primary driver is fluctuating and declining estrogen. Estrogen receptors are present throughout cardiac tissue and the autonomic nervous system; as estrogen levels become erratic during perimenopause, the autonomic balance between sympathetic and parasympathetic tone shifts, increasing heart rate variability and the likelihood of ectopic beats. Three overlapping mechanisms are proposed:

1. Vasomotor coupling — hot flashes trigger a surge in sympathetic activity that transiently elevates heart rate, producing the pounding sensation.
2. Autonomic dysregulation — reduced estrogen impairs baroreflex sensitivity, making the heart more reactive to everyday stressors.
3. Psychological amplification — anxiety and depression, which are more prevalent during perimenopause, lower the threshold at which a person notices and is distressed by normal cardiac variation.

Contributing factors identified in the SWAN (Study of Women's Health Across the Nation) longitudinal cohort include poor sleep, perceived stress, depressive symptoms, and higher body mass index. Caffeine, alcohol, nicotine, and certain decongestants or herbal stimulants can worsen palpitation frequency regardless of menopausal status.

Symptoms and diagnosis

Patients typically describe one or more of the following:

• A fluttering or "flip-flop" sensation in the chest
• A brief racing heartbeat, often lasting seconds to a few minutes
• A feeling that the heart has "skipped" or "stopped" momentarily
• Pounding in the throat or neck

These episodes may occur at rest, during a hot flash, at night, or with emotional stress. Palpitations that are brief, infrequent, and resolve on their own are usually benign. Red-flag features that warrant urgent evaluation include palpitations accompanied by chest pain, syncope or near-syncope, shortness of breath, or palpitations that are sustained (lasting more than a few minutes).

Diagnosis begins with a thorough history and a 12-lead ECG. If the ECG is normal and symptoms are infrequent, a 24- to 48-hour Holter monitor or a 2-week event recorder may be ordered. Blood work — available through LifeLabs or Dynacare across most Canadian provinces — typically includes TSH (to rule out thyroid dysfunction), a complete blood count (to rule out anemia), and an electrolyte panel. Echocardiography is added if structural heart disease is suspected.

Feature	Likely benign (menopausal)	Warrants urgent workup
Duration	Seconds to 1–2 minutes	Sustained (> 5 minutes)
Associated symptoms	Hot flash, anxiety	Chest pain, syncope, dyspnea
ECG finding	Normal sinus rhythm or isolated ectopics	SVT, AF, prolonged QT, WPW
Onset	Perimenopausal age, no prior cardiac history	Any age, known cardiac disease
Response to rest/relaxation	Resolves	Persists

Treatment options

Management follows a stepwise approach, moving from lifestyle modification to pharmacotherapy only when symptoms are frequent or distressing.

Lifestyle measures with evidence for reducing palpitation frequency include limiting caffeine and alcohol, stopping smoking, maintaining adequate hydration (approximately 2–2.5 L/day), and structured stress-reduction practices such as cognitive behavioural therapy (CBT) or mindfulness-based stress reduction.

Hormone therapy (HT) is the most effective treatment for vasomotor symptoms and, by extension, for palpitations that are tightly coupled to hot flashes. A 2022 systematic review in Climacteric found that menopausal hormone therapy reduced palpitation frequency in multiple randomized trials. The Society of Obstetricians and Gynaecologists of Canada (SOGC) supports HT as first-line therapy for bothersome vasomotor symptoms in appropriate candidates. In Canada, HT is available through family physicians and gynaecologists, and through virtual menopause care platforms such as Felix, Cleo, Maple, and others, though formulary coverage varies by province.

Non-hormonal pharmacotherapy — including SSRIs (paroxetine, escitalopram), SNRIs (venlafaxine), and gabapentin — can reduce vasomotor symptoms and may secondarily reduce palpitation burden, particularly when anxiety or depression is a contributing factor.

Beta-blockers (e.g., metoprolol) are sometimes prescribed short-term for symptomatic relief of frequent ectopic beats, though evidence specific to menopausal palpitations is limited.

When to see a clinician in Canada

See a family physician or nurse practitioner promptly if palpitations are new, frequent (more than a few times per week), or associated with any red-flag features listed above. Canadians can access initial assessment through their primary care provider, a walk-in clinic, or a virtual care platform. If an arrhythmia is confirmed or suspected, referral to a cardiologist or an electrophysiologist is appropriate. Women with a personal or family history of long QT syndrome, hypertrophic cardiomyopathy, or atrial fibrillation should not assume palpitations are menopausal without cardiac clearance first.

Limitations and open questions

Research is still emerging on the precise mechanisms linking estrogen withdrawal to specific arrhythmia subtypes. The SWAN cohort data are observational, so causality between menopausal stage and palpitation trajectories cannot be fully established. Most treatment trials have used palpitations as a secondary outcome rather than a primary endpoint, meaning effect sizes are imprecise. Health Canada has not issued specific guidance on palpitations as a standalone menopausal symptom, and Canadian-specific prevalence data are limited. It also remains unclear whether perimenopausal palpitations independently predict long-term cardiovascular risk or whether they are simply a marker of vasomotor symptom burden. Clinicians and patients should weigh these uncertainties when making treatment decisions.